Biologics for thyroid eye disease

Marius N. Stan, James A.Leon Garrity, Barbara G. Carranza, Thapa Prabin, Elizabeth A. Bradley, Rebecca S. Bahn, Mario Salvi, Guia Vannucchi, Nicola Currò, Irene Campi, Danila Covelli, Davide Dazzi, Simona Simonetta, Claudio Guastella, Lorenzo Pignataro, Sabrina Avignone, Paolo Beck-Peccoz, Jose V. Perez-Moreiras, Juan J. Gomez-Reino, Jose R. ManeiroEva Perez-Pampin, Angel Romo Lopez, Fernando M.Rodríguez Alvarez, Jesús M.Castillo Laguarta, Aurora del Estad Cabello, María Gessa Gregori Sorroche, Enrique España, Marco Sales-Sanz, Terry J. Smith, George J. Kahaly, Daniel G. Ezra, James C. Fleming, Roger A. Dailey, Rosa A. Tang, Gerald J. Harris, Alessandro Antonelli, Mario Salvi, Robert A. Goldberg, James W. Gigantelli, Steven M. Couch, Erin M. Shriver, Brent R. Hayek, Eric M. Hink, Richard M. Woodward, Kathleen Gabriel, Guido Magni, Raymond S. Douglas

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Biologic therapy, and particularly teprotumumab, can achieve disease-modifying response without the adverse effects of systemic steroids for active thyroid eye disease. The following manuscripts detail the evidence behind various steroid-sparing biologic agents for thyroid eye disease.

Original languageEnglish (US)
Title of host publicationFoundational Papers in Oculoplastics
PublisherSpringer International Publishing
Pages481-498
Number of pages18
ISBN (Electronic)9783030927943
ISBN (Print)9783030927936
DOIs
StatePublished - Jan 31 2022

Keywords

  • Graves' disease
  • Hyperthyroidism
  • Rituximab
  • Teprotumumab
  • Thyroid eye disease
  • Tocilizumab

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Biologics for thyroid eye disease'. Together they form a unique fingerprint.

Cite this